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Abstract
Background—Sleep apnea is a common condition and has a direct impact on cognitive function. 
The impact of sleep apnea, and its interplay with other established risk factors on the risk of 
incident dementia, warrants exploration.
Objectives—To investigate the association between baseline sleep apnea and risk of incident 
dementia in the Prevention of Alzheimer’s Disease with Vitamin E and Selenium (PREADViSE) 
study and explore whether the association depends on APOE ε4 allele status.
Design—Secondary analysis based on data collected during PREADViSE.
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Setting—Participants were assessed at 128 local clinical study sites during the clinical trial phase 
and later were followed by telephone from a centralized location.
Participants—7,547 male subjects were enrolled in PREADViSE.
Measurements—Participants were interviewed at baseline for sleep apnea. The Memory 
Impairment Screen (MIS) was administered to each participant annually. Subjects who failed to 
this initial screen were tested with secondary screening tests. Additional measures collected 
include medical history, medication use, and the AD8 dementia screening instrument.
Results—The effect of self-reported sleep apnea on dementia risk depended on APOE ε4 status. 
When the allele was absent, baseline self-reported sleep apnea was associated with a 66% higher 
risk of developing dementia (95% CI 2%–170%), while self-reported sleep apnea conferred no 
additional risk for participants with an ε4 allele.
Conclusion—Sleep apnea may increase risk of dementia in the absence of APOE ε4. This may 
help inform prevention strategies for dementia or AD in older men with sleep apnea.
Registration—PREADViSE is registered at ClinicalTrials.gov: NCT00040378.
Keywords
self-reported sleep apnea; dementia; APOE
INTRODUCTION
Dementia is a syndrome that affects memory, thinking, behavior and ability to perform 
everyday activities. In 2010, Wimo and colleagues estimated global dementia prevalence at 
35.6 million people, and this number is expected to double by 2030 and more than triple by 
2050. Moreover, estimated annual costs of dementia reached $604 billion (U.S. dollars) in 
2010[1, 2]. With rising prevalence, these costs are expected to increase by 85% by 2030, 
which would make dementia the most expensive chronic disease associated with aging.
Sleep apnea is a common age-associated type of sleep disordered breathing (SDB), with 
clinical symptoms including loud snoring, breathing pauses such as choking or gasping 
during sleep, morning headaches, insomnia, and daytime sleepiness [3–5]. Sleep apnea and 
risks associated with it, such as obesity, are becoming an increasingly important public 
health issues for adults [3, 4, 6–9]. The prevalence of sleep apnea varies by age and sex and 
is more common in older adults and men [4, 10, 11]. It is estimated to be present in 20 to 
50% of older adults [4]. For people aged 50–70 years old, 17% of men and 9% of women 
are estimated to have moderate-to-severe SDB [12].
Sleep apnea is associated with cognitive impairment and dementia in older populations [13, 
14]; however, the relationship between pre-existing sleep apnea and incident cognitive 
impairment and dementia remains poorly characterized. Many existing studies are limited by 
cross-sectional study designs, small sample size, or short follow-up time [15, 16]. Three 
cross-sectional studies in populations aged over 65 years found no association between the 
apnea-hypopnea index and cognitive function [17–19]. By contrast, in a prospective study of 
298 women, Yaffe et al. [20] found that SDB was associated with a 71% increased risk of 
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developing mild cognitive impairment (MCI) or dementia over 5 years after adjusting for 
age, race, body mass index, education level, smoking status, presence of diabetes, and 
hypertension. A retrospective population-based study also showed increased risk of 
developing dementia for a Taiwanese population aged over 40 years who participated in a 
national health insurance program [21]. Sleep apnea patients had a 170% increase in 
dementia risk compared with patients without sleep apnea after adjustment for age, sex, 
hypertension, diabetes, stroke, and hyperlipidemia during the 5-year follow-up period [21]. 
Finally, an eight-year study of older adults found only small effects of SDB on decline in 
attention, but not memory, once other medical comorbidities were included in their statistical 
models[14].
However, these cohort studies were unable to consider the effect of the genetic risk factor, 
APOE [22], on risk of dementia. Since APOE is a major unmodifiable risk factor for 
dementia due to Alzheimer’s disease (AD), the most common form of dementia, it is 
important to understand whether sleep apnea or SDB might differentially influence the risk 
of dementia based on the status of APOE genotype. To our knowledge, only three studies 
have explored this association. O’Hara et al. conducted a small cross-sectional study (n=36) 
and found that SDB was only associated with impairment of verbal memory in APOE ε4 
allele carriers [23], while Osorio and colleagues (n=95) found only a trend toward lower 
CSF Aβ-42 levels in APOE ε4 positive normal older adults with SDB [6]. A second study 
by Osorio and colleagues based on the Alzheimer’s disease Neuroimaging Initiative 
database (n=2,285) found that SDB was associated with younger age at onset of MCI, and 
this was not affected by APOE ε4 carrier status [24]. Additional studies are needed to 
investigate this topic.
Using Prevention of Alzheimer’s Disease (AD) by Vitamin E and Selenium (PREADViSE) 
trial data, which comprises 7,547 male subjects who were free from dementia at baseline, we 
sought to investigate two research hypotheses: (1) older men with self-reported sleep apnea 
prior to cognitive impairment have an increased risk of dementia, and (2) older men with 
self-reported sleep apnea have different risks for dementia based on APOE allele status.
METHODS
Study population and data sources
We conducted a secondary analysis of sleep apnea and incident dementia among 7,547 
subjects enrolled in the PREADViSE trial [25]. The PREADViSE trial is an ancillary study 
to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (a large prostate cancer 
prevention randomized controlled trial (RCT)) [26] and was designed to evaluate the 
effectiveness of antioxidant supplements vitamin E and selenium in preventing incident AD 
and other forms of dementia. PREADViSE investigators were blind to SELECT treatment 
assignment as of this writing, and so the effects of the antioxidant supplements will not be 
considered further here. During the recruiting period from 2002 to 2009, PREADViSE 
enrolled 7,547 non-demented male participants age 62 years and older (age 60 if African 
American) from 128 participating SELECT clinical sites in the US, Canada, and Puerto 
Rico. The eligibility criteria for participating in PREADViSE included active SELECT 
enrollment at a participating site and absence of dementia and other active neurologic 
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conditions that affect cognition such as major psychiatric disorder, including depression. All 
7,547 participants are included in the current study; no further inclusion and/or exclusion 
criteria were applied for this secondary analysis.
The study supplements in SELECT were discontinued by its Data Safety Monitoring 
Committee in 2008 following a futility analysis [27]; PREADViSE and SELECT then 
continued as observational exposure cohort studies. The details of this evolution for 
PREADViSE can be found in Kryscio et al. [28]. All participants were asked to continue in 
the exposure study, and 4,271 of 7,547 original PREADViSE volunteers consented to 
participation (Figure 1). PREADViSE was approved by the University of Kentucky 
Institutional Review Board (IRB) as well as the IRBs at each SELECT study site. Each 
participant provided written informed consent. During the RCT phase, SELECT sites used a 
web-based data collection system to submit data directly to the Cancer Research and 
Biostatistics Group, who managed the data for SELECT. SELECT provided monthly 
snapshots of PREADViSE data elements to PREADViSE via a secure file transfer protocol 
(ftp) site. During the observational phase, data were collected at a single site, the University 
of Kentucky.
Case Ascertainment
The Memory Impairment Screen (MIS) [29] was used as the primary screening instrument 
for dementia in both the RCT and observational portions of PREADViSE. The MIS was 
given annually. If participants failed the MIS (that is, the participant scored 5 or less out of 8 
on either the immediate or delayed recall portion of the MIS), a second tier screen was 
administered. An expanded Consortium to Establish a Registry in AD battery (CERAD-e) 
[30] was used during the RCT period and the modified Telephone Interview for Cognitive 
Status (TICS-m) [31], was used during the observational study. Both the CERAD-e and the 
TICS-m assessed participants’ global cognitive function. Failure on the secondary screen (T 
score ≤ 35 on CERAD-e battery or total score ≤ 35 on TICS-m) would lead to a 
recommendation for a clinic visit with their local physician. Records from the clinic visit 
were reviewed by 3–5 expert clinicians, including two neurologists and at least one 
neuropsychologist, for a consensus diagnosis. In cases where the neurologists disagreed in 
their diagnoses, the study PI made the final determination. Annual screenings were 
completed in May 2014, and a small number of participants were followed for medical 
records through August 2015.
The incident dementia cases were identified through two methods. First, as described above, 
a medical records-based consensus diagnosis was used. Date of diagnosis was assigned as 
the date of the failed screen. Second, because many participants were reluctant to obtain 
medical workups for their memory, additional longitudinal measures including the AD8 
Dementia Screening Interview [32], self-reported medical history, self-reported diagnosis of 
dementia, use of memory enhancing prescription drug, and cognitive scores including the 
MIS, CERAD-e T Score, NYU Paragraph Delayed Recall, and TICS-m were used to 
identify cases. The diagnostic criteria for the second method were AD8 total of ≥ 1 (at any 
time during follow-up) to indicate functional impairment [32] plus one of the following: a 
self-reported diagnosis of dementia, use of a memory enhancing prescription drug 
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(donepezil, rivastigmine, galantamine, or memantine), or cognitive score below cutoffs for 
intact cognition on any test (for example: 1.5 SDs below expected performance based on age 
and education normative data[3]. The date of diagnosis was assigned to the earliest event.
Sleep Apnea
All participants were asked during the baseline PREADViSE interview whether they had 
ever been treated for sleep apnea. Responses were recorded as “yes” or “no.”
APOE genotype
APOE ε4 positivity is a major risk factor for AD-type dementia [4]. APOE genotype was 
obtained for 7,180 participants (ε2/2: 51 (0.71%); ε2/3: 879 (12.24%); ε2/4: 190 (2.65%); 
ε3/3: 4,320 (60.17%); ε3/4: 1,599(22.17%); ε4/4: 141(1.96%)). The genotypes were 
converted to a dummy indicator for at least one ε4 allele, where the presence of at least one 
ε4 allele was considered a carrier. SAS 9.4® procedure PROC MI was used to impute 
missing values for the indicator variable (367/7547 (5%)) based on family history of 
dementia. Four imputed data sets were generated; participants with two or more positive 
imputations for APOE ε4 were coded as APOE ε4 positive.
Other Covariates
Other data collected included age at baseline, race, body mass index (BMI), years of 
education, as well as self-reported indicators of cardiovascular disease (i.e., diabetes, 
hypertension, and smoking). These are recognized risk factors for dementia [5]. History of 
significant cognitive or motor impairment due to stroke was a PREADViSE exclusion 
criterion so baseline prevalence of stroke in the cohort is extremely low (0.6%), thus stroke 
was not considered further.
Statistical analysis
Chi-square and t test statistics were used to examine differences in categorical and 
continuous variables between sleep apnea groups. The log-rank test was used to assess 
differences in crude cumulative risk of dementia between sleep apnea groups. A series of 
Cox proportional hazards regression models with self-reported sleep apnea as the 
independent variable, survival time to diagnosis of dementia as the dependent variable, and 
the covariates listed above were applied to simple and multivariable survival analyses, where 
follow-up time was defined as the period in years between date of PREADViSE study entry 
and date of dementia diagnosis or, in the absence of dementia, date of last assessment. The 
multivariable model included main effects for baseline age, years of education, body mass 
index (BMI), race (black vs. non-black), APOE (presence of APOE ε4 or absence of APOE 
ε4), smoking (yes vs. no), self-reported baseline status of diabetes and hypertension (coded 
present or absent). Covariates were fixed at baseline. The proportional hazards assumption 
was tested by checking the interaction between time and each covariate. Interaction terms 
between history of sleep apnea and each covariate in the model were also tested. None of the 
interactions were significant. Given the sufficient sample size in each APOE group (n = 
2029 and 5518 in APOE ε4 positive group and negative group, respectively), we also 
evaluated the effect of sleep apnea on risk of dementia stratified by APOE ε4 to evaluate for 
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effect modification between sleep apnea and APOE. All data were analyzed by using SAS 
9.4® (SAS Institute, Inc., Cary, NC), and 0.05 was set as the significance level.
RESULTS
Demographic attributes of participants from PREADViSE are shown in Table 1. Briefly, 
7.3% (552/7547) of the men reported history of sleep apnea at baseline. The absolute 
difference in baseline age between men with and without sleep apnea was significant but not 
large (Table 1). Men with history of sleep apnea at baseline were significantly more likely to 
be of black race (p = 0.02), smokers (p<0.001), have higher BMI (p < 0.001), and were more 
likely to report hypertension (p<0.001) and diabetes (p<0.001). No significant differences 
were observed in educational attainment or proportion of APOE ε4 carriers.
A total of 310 (4.1%) men were diagnosed with dementia (4.0% for men without sleep 
apnea, 5.1% for men with history of sleep apnea, respectively; p = 0.24). The cumulative 
incidence accounting for censoring during follow-up was estimated to be 9.3% in the non-
sleep apnea group and 24.4% in sleep apnea group (Figure 2). However, this difference was 
not significant due to the relatively small number of dementia cases in the sleep apnea group 
(p = 0.14 by the log-rank test).
Table 2 displays hazard ratios for dementia diagnosis from adjusted Cox models. History of 
sleep apnea was borderline significant in the adjusted model (HR = 1.44; 95% CI 0.96 – 
2.17, p = 0.08). In this adjusted analysis, men with sleep apnea were more likely to develop 
dementia compared to men without sleep apnea. Black race, APOE ε4 carrier status, and 
baseline age were significantly associated with dementia risk. Interaction terms between 
sleep apnea and each covariate in the model were tested, but none were significant.
Stratified analyses by status of APOE ε4 were conducted, and results are shown in Table 2. 
For men without an APOE ε4 allele, history of sleep apnea conferred a 66% (95% CI 2%–
170%) higher risk of developing dementia (Figure 3a). Sleep apnea had no effect when the 
APOE ε4 allele was present (Figure 3b).
DISCUSSION
In this study, self-reported baseline history of sleep apnea was borderline significantly 
associated with risk of dementia after adjustment for confounding (p = 0.08). Stratified 
analysis by APOE ε4 carrier status showed that baseline history of sleep apnea was 
associated with significantly increased risk of dementia in non-carriers. For the latter, self-
reported sleep apnea was estimated to confer a 66% higher risk to develop dementia (p = 
0.0423). Age, race, and APOE were significantly associated with the risk of dementia in the 
multivariable Cox model. We did not find any significant associations for years of education, 
smoking, BMI, presence of diabetes, or hypertension in either the primary or the stratified 
analyses with the exception of smoking, which significantly increased risk for APOE ε4 
carriers. None of the two-way interactions between self-reported sleep apnea and other 
covariates were significant, including APOE ε4, which was likely due to a lack of sufficient 
statistical power to detect the interaction despite the difference in the stratified analysis.
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There are very few prospective studies that have investigated the association between sleep 
apnea and risk of dementia in an older adult male population. We did not find clear evidence 
that history of sleep apnea, prior to cognitive impairment, was associated with dementia in 
men overall, which is similar to the findings reported in Osorio’s recent study [24] and 
several other cross-sectional studies [17–19]. However, our results did show that sleep apnea 
is significantly associated with dementia risk for men who were APOE ε4 allele non-
carriers. This is contradictory to the finding of one small cross-sectional study [23], which 
found that the association existed only for APOE ε4 allele carriers, but similar to Osorio et 
al.’s study [6], in which CSF amyloid beta 42 and tau were not associated with sleep apnea 
in APOE ε4 allele carriers but were associated in noncarriers [6]. Such discrepancies are 
likely the result of differences in exposure and outcome assessment, residual confounding, 
covariates adjusted for, sample size, study population, or study design.
Similar to other studies [6, 23], our results indicated an interaction effect of sleep apnea and 
APOE ε4 on the risk developing dementia. This is particularly important considering both 
the high prevalence of sleep apnea in older populations [4] and the high percentage of APOE 
ε4 non-carriers in the population (~75%) [33]. So far, several prevention trials [14, 33] have 
been completed with null or inconclusive results. Since the APOE ε4 allele is a well-known 
and non-modifiable risk factor for AD, the findings of this study may help inform prevention 
strategies for dementia or AD in older men with sleep apnea. Osorio and colleagues [32] 
suggest that treatment with continuous positive airway pressure (CPAP) may delay onset of 
MCI. It is of course important that all patients with sleep apnea are diagnosed and treated, 
but diagnosis and treatment of sleep apnea may be especially helpful in preventing or 
delaying incident cognitive impairment in the aging male population with SDB who are 
APOE ε4 non-carriers.
Possible mechanisms that could explain the association of sleep apnea with risk of incident 
cognitive decline and dementia include direct effects on cerebral oxygenation and the 
selective vulnerability of hippocampal neurons to hypoxia, or perhaps augmentation of 
vascular contributions that have been strongly linked to the development of MCI, AD, and 
other forms of dementia [20, 35]. Chronic hypoxia has been linked to hippocampal injury 
that may lower the threshold for the development and or spread of tau-associated 
neurodegeneration [36]. The development of sleep apnea has also been shown to exacerbate 
cardiovascular risk factors such as hypertension, and to be strongly associated with obesity, 
insulin resistance, hyperlipidemia, and the development of the metabolic syndrome [29, 37]. 
Thus, there may be many ways that sleep apnea contributes to derangements in metabolic 
pathways that have been strongly associated with increased risk of incident MCI or dementia 
in the aging population. Indeed, the present data demonstrate increased prevalence of 
hypertension and diabetes in those with sleep apnea, although the association with APOE 
status appeared independent of such conditions in the adjusted analysis, suggesting that 
other mechanistic factors may be important to consider.
Another possible mechanism for the association of sleep apnea and risk of dementia is that 
sleep may help regulate brain amyloid-β levels [38, 39]. A recent study in transgenic mice 
demonstrated that levels of brain amyloid-β increased when both normal and AD mouse 
models were awake and then decreased during sleep [40]. This diurnal variation in amyloid 
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production could be dramatically altered in persons with sleep apnea or other sleep 
disturbances [41]. A small study [42] of community-based older adults was able to 
demonstrate that shorter sleep duration was significantly associated with increased amyloid-
β levels. There is also some evidence that APOE might play a role in degradation of 
amyloid-β [3]. APOE ε4 carriers show lower concentration of amyloid-β in the 
cerebrospinal fluid, indicating increased amyloid-β deposition in the brain [6]. In the 
presence of APOE ε4, any increase in brain amyloid-β associated with sleep apnea may be 
overwhelmed by that due to APOE ε4 alone. However, it remains unclear why amyloid-β is 
affected by the sleep cycle or how it depends on the APOE genotype. [44]
This study has some limitations. Not all participants who failed the memory screenings were 
willing to visit their doctors for a memory work-up, so case ascertainment may be less 
accurate due to lack of medical records. However, application of the secondary dementia 
criteria (positive AD8 screen, self-reported diagnosis, use of memory enhancing drug, and 
poor cognitive scores) demonstrated good agreement in the cases where the diagnosis was 
known (data not shown). Because only a subset of subjects participated in both the RCT as 
well as the exposure phases of PREADViSE, some cases may have been missed among the 
subjects who did not participate in the exposure study. Our data show there were 46.2% 
participants who had sleep apnea at baseline and did not continue to participate in the study, 
while 50.1% subjects without sleep apnea in the baseline cohort did not continue. Therefore, 
the loss of cases would be estimated to be the same for the subjects with and without sleep 
apnea. We measured sleep apnea with self-report, similar to Osorio et al. [24]. Due to the 
phrasing of the questionnaire, undiagnosed and or untreated sleep apnea subjects may have 
been missed [45]. However, because ascertainment of sleep apnea occurred at baseline, it is 
independent of dementia ascertainment. Therefore, if there is misclassification of sleep 
apnea exposure, it is non-differential misclassification, and will bias the association toward 
the null [44], that is, to lessen the degree of association. Thus, our analysis likely 
underestimates the effect of sleep apnea on dementia risk. Since the study population is all 
older men, the findings from this study cannot be generalized to older women. However, the 
current findings align quite well with those reported by Yaffe and colleagues who showed an 
increased risk for dementia with SDB in older women [20]. Strengths for the study include 
the large sample and long follow-up. We were also able to consider most well established 
risk factors for dementia including demographic, genetic, and medical characteristics, 
including cardiovascular risk factors.
CONCLUSION
Our study provides evidence that in the absence of APOE ε4, sleep apnea may increase the 
risk of dementia in older men. This may occur through the disruption of brain amyloid-β 
regulation that occurs during the sleep cycle, or through cerebrovascular damage, although 
the exact mechanism remains unclear [43]. Considering the limited number of publications 
in this area and the inconsistent findings, replication studies with objective measures of sleep 
apnea, long follow-up, and rigorous methods to diagnose dementia are needed to support 
this finding conclusively.
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From the standpoint of clinical practice, many primary care physicians are unaware of their 
patients’ genetic status and APOE genotype in particular. However, with adequate screening 
of SDB symptoms along with other risk factors (e.g., age, ethnicity) our findings along with 
those of O’Hara et al. [23] and Yaffe et al. [20] we would advise the clinician to work with 
all their patients to address sleep apnea problems as soon as possible given the association 
with future cognitive dysfunction.
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Participant flow diagram for PREADViSE
*PREADViSE was an ancillary study to SELECT; enrollment was from May 2002 through 
November 2009 (N=7,547). PREADViSE participants were invited to participate in 
centralized follow-up (PREADViSE CFU) following the closure of SELECT due to a futility 
analysis. Some SELECT sites decided not to offer their participants the opportunity to 
participate in CFU; these participants are listed above as being ineligible. PREADViSE CFU 
continued to follow participants from August 2010 – August 2015.
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Probability of dementia by history of sleep apnea (SDB) at baseline. Solid line indicates 
sleep apnea, dashed line indicates no sleep apnea. Time axis ends at 10 years for consistency 
among figures.
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Figure 3a & 3b. Probability of dementia at baseline by history of sleep apnea (SDB) status 
after adjusting other covariates in APOE ε4 non-carriers (a) and carriers (b). These 
hypothetical participants are white, age 68 at baseline, smoke, have 15 years of education 
and baseline BMI 28.5 kg/m2, and comorbidities including presence of hypertension and 
diabetes. Solid line indicates sleep apnea, dashed line indicates no sleep apnea. Time axis 
ends at 10 years for consistency among figures.
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Table 1
General Characteristics of the Study Population in PREADViSE
Characteristic All Subjects (N=7,547) No Sleep Apnea (n=6,995) Sleep Apnea (n=552) P value
Baseline agea, y, mean±SD 67.5±5.3 67.6±5.3 66.6±4.5 < 0.001
Educationc, y, mean±SD 15.0±2.7 14.9±2.7 15.1±2.6 NSb
Black race 756 (10.0) 685 (9.8) 71 (12.9) 0.02
Baseline smokingd 4260 (56.6) 3916 (56.1) 344 (62.4) 0.004
APOE-ε4 (≥1 ε4) 2,029 (26.9) 1876 (26.8) 153 (27.7) NSb
Baseline hypertension 2,998 (39.7) 2703 (38.6) 295 (53.4) <0.001
Baseline diabetes 858 (11.4) 762 (10.9) 96 (17.4) <0.001
Baseline BMIef, kg/m2, mean±SD 28.5±4.4 28.2±4.2 31.6±5.3 <0.001
Follow-up time, y, mean±SD 5.7±2.8 5.7±2.8 5.5±2.8 NSb
a




N = 7,512 for education;
d
N = 7528 for smoking;
e
BMI: Body Mass Index;
f
N = 7515 for BMI.
Note: Results presented are mean±SD or N (%). All PREADViSE participants are male.
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Table 2
Association between History of Sleep Apnea and Risk of Dementia based on Adjusted Cox Model and 
Stratified Analysis by APOE ε4 Status
Adjusted HRb (95% CI)
Stratified Analysis
Adjusted HRb (95% CI)
APOE ε4 carriers (N = 2,029) APOE ε4 non-carriers
Sleep apnea 1.44 (0.96–2.17) 1.13 (0.54–2.37) 1.66 (1.02–2.70)
Baseline age, 1 year 1.11 (1.09–1.13) 1.14 (1.10–1.17) 1.09 (1.07–1.12)
Education, 1 year 0.98(0.94–1.02) 1.01 (0.94–1.08) 0.95 (0.91–1.01)
Black race 1.73 (1.19–2.52) 1.71 (0.97–3.03) 1.72 (1.05–2.82)
Baseline smoking 1.20 (0.95–1.51) 1.55 (1.06–2.26) 1.03 (0.77–1.38)
APOE ε4 carrier 1.99 (1.58–2.50) -- --
Baseline HTNc 0.92 (0.73–1.17) 0.83 (0.56–1.21) 0.98 (0.72–1.33)
Baseline diabetes 1.10 (0.78–1.57) 0.83 (0.43–1.58) 1.29 (0.85–1.97)
BMId,, 1 kg/m2 0.99 (0.97–1.02) 1.00 (0.95–1.04) 0.99 (0.96–1.03)
a






BMI = body mass index.
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